Resultados de búsqueda - Carlos Gomez-Roca

A double-edged sword: unusual multiple severe infections with pralsetinib: a case report and literature review por François Poumeaud, Marion Jaffrelot, Carlos Gomez-Roca, Iphigénie Korakis, Giulia Leonardi, Marine Joly, Julien Mazières, Rosine Guimbaud, Nadim Fares, Nadim Fares, Emily Alouani, Emily Alouani

Enlace del recurso

1521 Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer: a joint analysis of the REGOMUNE and RE... por Kohei Shitara, Antoine Adenis, Antoine Hollebecque, Antoine Italiano, Shohei Koyama, Hiroyoshi Nishikawa, Carlos Gomez-Roca, Philippe Cassier, Alban Bessede, Jean-Philippe Metges, Sophie Cousin, Jean-Philippe Guégan, Shota Fukuoka, Lola-Jade Palmieri

First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumou... por Stephane Champiat, Francois-Xavier Danlos, Aurélien Marabelle, Ignacio Melero, Carlos Gomez-Roca, Aurelie Petain, Claire Fabre, Eduardo Castañón Álvarez, Philippe Alexandre Cassier, Elena Dupuy, David Jegou, Marie Primard, Mathilde Saccareau, Geneviève Gueguen-Dorbes

Enlace del recurso

721 Ongoing phase 1 study of MP0317, a FAP-CD40 DARPin, shows a favorable safety profile and early evidence of tumor-localized CD40 activation in patients with advanced solid tumor... por Anne Goubier, Neeltje Steeghs, Carlos Gomez-Roca, Philippe Cassier, Elena Fernandez, Eelke Gort, Hilde De Winter, Vaia Stavropoulou, Nina Stojcheva, Paul Baverel, Jennifer Krieg, Kyriaki Ioannou, Ana Maria Florescu, Lea Hoenig, Bruno Baud-Berthier, Michael P Sanderson, Vladimir Kirkin, Philippe Legenne

Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers por Stephane Champiat, Elena Garralda, Vladimir Galvao, Philippe A. Cassier, Carlos Gomez-Roca, Iphigenie Korakis, Peter Grell, Aung Naing, Patricia LoRusso, Romana Mikyskova, Nada Podzimkova, Milan Reinis, Kaissa Ouali, Andreu Schoenenberger, Joachim Kiemle-Kallee, Sascha Tillmanns, Richard Sachse, Ulrich Moebius, Radek Spisek, David Bechard, Lenka Palova Jelinkova, Irena Adkins, Aurelien Marabelle

Enlace del recurso

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients por Jean-Marie Michot, Wolfgang Jacob, Francesca Michielin, Martin Weisser, Dmitriy Zamarin, Jean-Pascal Machiels, Anna-Maria Jegg, Dominik Rüttinger, Konstanty Korski, Jean-Pierre Delord, Carlos Gomez-Roca, Tara Mitchell, Gaetan Catala, Lauriane Eberst, Michael A Cannarile, Carl Watson, Galina Babitzki, Irina Klaman, Priscila Teixeira, Sabine Hoves, Carola Ries, Georgina Meneses-Lorente, Randolph Christen, Philippe Cassier

Enlace del recurso

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study por Yonina R. Murciano-Goroff, Antoine Hollebecque, Rebecca S. Heist, Philippe A. Cassier, Ji-Youn Han, So Yeon Kim, Joshua K. Sabari, Diego Tosi, Adrian Sacher, Timothy F. Burns, Toshio Shimizu, Natraj Reddy Ammakkanavar, Alexander Spira, Carlos Gomez-Roca, Amita Patnaik, Rasha Cosman, J. Nicholas Bodor, Misako Nagasaka, Arthur Xintian You, Samuel C. McNeely, Raimund Peter, Aaron Fink, Aaron Chen, Geoffrey R. Oxnard, Melinda D. Willard, Yasutoshi Kuboki, Takafumi Koyama

Enlace del recurso